- Adults (18-64 years)
- General population
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
Central Data Repository
Explore the Central Data Repository: Use the filters and keyword search box on the left to find relevant studies. As you refine your search, the map and study list will automatically update to reflect your selections. Selecting a study from the list will provide detailed information about the specific study in question. A full legend can be found here
{content}
Study list
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Immunoadsorption
- Adults (18-64 years)
- General population
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- Fimo Health App
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Fragile population
- Hospital
- Emergency department
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Remdesivir
- Sotrovimab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Adults (18-64 years)
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- Telemedicine
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Primary care
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Primary care
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Infectious diseases unit
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Remdesivir
- Sotrovimab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Psychotherapy
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- Neurostimulation
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Digital health
- Adults (18-64 years)
- General population
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- General population
- Infants (<1 year)
- Children (1-11 years)
- Adolescents (12-17 years)
- Hospital
- Outpatient clinic
- Monkeypox virus
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Psychotherapy
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Monkeypox virus
- Pharmacological intervention
- Antivirals
- Tecovirimat
- Adults (18-64 years)
- General population
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- Elderly (≥65 years)
- Community
- Arbovirus
- Chikungunya virus
- Vector-borne
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Lifestyle intervention
- Education
- Therapeutic Exercise
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Pharmacological intervention
- Anti-depressant
- Tianeptine
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- Telemedicine
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- Breathing therapy
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome